Literature DB >> 6402063

Neurological effects of recombinant human interferon.

H Smedley, M Katrak, K Sikora, T Wheeler.   

Abstract

Ten women with advanced locally recurrent breast cancer who had failed to respond to radiation and hormonal and cytotoxic agents were given up to 12 weeks of recombinant leucocyte interferon 20 X 10(6) U/m2 daily or 50 X 10(6) U/m2 three times a week. Within one hour of administration influenza-like symptoms began, which one week later were superseded by lethargy, anorexia, and nausea, with a consequent loss of weight in most patients. Other side effects included profound somnolence, confusion, paraesthesia, and (in one patient) signs of an upper motor neurone lesion in the legs. All these effects together with increased slow wave activity in electroencephalograms from all patients during treatment disappeared when interferon was withdrawn and did not recur on reintroducing the drug at a lower dosage. Studies are continuing to determine the mechanisms of these effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402063      PMCID: PMC1546481          DOI: 10.1136/bmj.286.6361.262

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  2 in total

1.  Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon.

Authors:  S Maeda; R McCandliss; M Gross; A Sloma; P C Familletti; J M Tabor; M Evinger; W P Levy; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

2.  Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.

Authors:  S J Horning; J F Levine; R A Miller; S A Rosenberg; T C Merigan
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

  2 in total
  29 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Exercise and sleep deprivation do not change cytokine expression levels in patients with chronic fatigue syndrome.

Authors:  Toru Nakamura; Stephan Schwander; Robert Donnelly; Dane B Cook; Felix Ortega; Fumiharu Togo; Yoshiharu Yamamoto; Neil S Cherniack; Marc Klapholz; David Rapoport; Benjamin H Natelson
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

3.  Are stress-induced immunological changes mediated by mood? A closer look at how both desirable and undesirable daily events influence sIgA antibody.

Authors:  A A Stone; C A Marco; C E Cruise; D S Cox; J M Neale
Journal:  Int J Behav Med       Date:  1996

4.  A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.

Authors:  K Sriskandan; P Garner; J Watkinson; K W Pettingale; D Brinkley; F M Calman; D E Tee
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia.

Authors:  Toru Nakamura; Stephan K Schwander; Robert Donnelly; Felix Ortega; Fumiharu Togo; Gordon Broderick; Yoshiharu Yamamoto; Neil S Cherniack; David Rapoport; Benjamin H Natelson
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

6.  Effect of interferon-alpha on DOI-induced wet-dog shakes in rats.

Authors:  A Kugaya; A Kagaya; Y Uchitomi; N Yokota; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  A Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo.

Authors:  Yanick J Crow; Pierre Lebon; Jean-Laurent Casanova; Ion Gresser
Journal:  J Clin Immunol       Date:  2018-09-05       Impact factor: 8.317

Review 8.  Cytokines in immune function and sleep regulation.

Authors:  James M Krueger; Jeannine A Majde; David M Rector
Journal:  Handb Clin Neurol       Date:  2011

9.  Remissions in newly diagnosed type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy.

Authors:  V A Koivisto; A Aro; K Cantell; M Haataja; J Huttunen; S L Karonen; P Mustajoki; R Pelkonen; P Seppälä
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

Review 10.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.